Oncology Institute Community

Fourth Quarter 2024 Financial Highlights Consolidated revenue of $100 million, an increase of 16.9% compared to the prior year quarter Gross profit of $15 million, an increase of 1.8% compared to the prior year quarter Net loss of $13.2 million compared to net loss of $18.8 million for the prior year quarter Basic and diluted loss per share of $(0.14) and $(0.14), respectively, compared to $(0.21) and $(0.21) for the prior year quarter Adjusted EBITDA of $(7.8) million compared to $(6.3) million for the prior year quarter Cash, cash equivalents, and investments of $50 million as of December 31, 2024 (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Read more

Key Takeaways Rapid expansion of value-based contracts and scaled risk-based care models is driving strong patient growth, margin expansion, and sustainable top-line gains. Market tailwinds, tech investments, and growing pharmacy operations position the company for durable demand, lower costs, and increased profitability.Read more